Oncology's trials. Market indicators

Nature Reviews Drug Discovery

Volumn 2, Issue 8, 2003, Pages 609-610

  Booth, Bruce ^a   Ma, Philip ^b   Glassman, Robert ^b,c  

^a MCKINSEY AND COMPANY   (United States)

^b 4 World Financial Center ^*  (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; GEFITINIB; METHOTREXATE; PREDNISONE; SEMAXANIB; THALIDOMIDE; VINCRISTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG APPROVAL; DRUG CONTROL; DRUG INDUSTRY; DRUG LABELING; DRUG MARKETING; DRUG RESEARCH; HUMAN; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MELANOMA; MYELOMA; NOTE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; STEM CELL TRANSPLANTATION; ARTICLE; STATISTICS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG APPROVAL; DRUG INDUSTRY; HUMANS;

EID: 0042067890     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1158     Document Type: Note

References (2)

1. Fossa, S. & Skovlund, E. Selection of Patients May Limit the Generalizability of Results from Cancer Trials, Acta Oncologica. 41, 131-137 (2002).
2. Stadtmauer E. et al. Conventional dose chemotherapy compared with high dose chemotherapy plusautologous hematopoietic stem cell transplantation for metastatic breast cancer. N. Engl. J. Med. 342, 1069-1076 (2000).